Search results
Results From The WOW.Com Content Network
The first edition of the Merck's Index was published in 1889 by the German chemical company Emanuel Merck and was primarily used as a sales catalog for Merck's growing list of chemicals it sold. [2] The American subsidiary was established two years later and continued to publish it.
catalogue chemicals CASno Structure SMILES "ChemExper". Chemxpert Database Chemxpert Chemical Database small molecules database buyers,suppliers "ChemxpertDB". 10,00000 Chemical Book East West University: commercially available compounds CASno, suppliers, properties "Chemical Book". 200,000 Chemical Register from 20,000 vendors
2014 – Merck KGaA announced that it would purchase Sigma-Aldrich for approx. $17 billion (€13.1 billion). [16] [17] November 3, 2014 – Sigma-Aldrich filed a definitive proxy statement with the U.S. Securities and Exchange Commission to hold a special investors meeting regarding approval for the sale to Merck KGaA. [18]
In 2011, seven months after Merck bought back the plant it sold just a few years earlier, company officials announced plans to sell off one product line and outsource others by the end of 2013 in ...
The Merck Manuals (outside the U.S. and Canada: The MSD Manuals; Chinese: 默沙东诊疗手册; pinyin: Mòshādōng Zhěnliáo Shǒucè) are medical references published by the American pharmaceutical company Merck & Co. (known as MSD outside the United States and Canada), that cover a wide range of medical topics, including disorders, tests, diagnoses, and drugs.
Merck (NYSE: MRK) Q3 2024 Earnings Call Oct 31, 2024, 9:00 a.m. ET. Contents: ... The trial met its primary endpoint of event-free survival and demonstrated an improvement in major pathological ...
The Merck Group, branded and commonly known as Merck, is a German multinational science and technology company headquartered in Darmstadt, with about 60,000 employees and a presence in 66 countries. The group includes around 250 companies; the main company is Merck KGaA in Germany. The company is divided into three business lines: Healthcare ...
Merck's new forecast includes a $0.26 per share charge for its $680 million acquisition of cancer drug developer Harpoon Therapeutics, which closed in the first quarter of 2024, the company said.